MAZE Maze Therapeutics Inc Forecast, Technical & Fundamental Analysis
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity... Show more
MAZE is expected to report earnings to rise 26.67% to -56 cents per share on November 05
Q3'26
Est.
$-0.57
Q1'26
Beat
by $0.13
Q4'25
Missed
by $0.02
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.15
The last earnings report on May 12 showed earnings per share of -44 cents, beating the estimate of -57 cents. With 182.90K shares outstanding, the current market capitalization sits at 1.43B.
A.I.dvisor indicates that over the last year, MAZE has been loosely correlated with AVXL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MAZE jumps, then AVXL could also see price increases.
MAZE in downward trend: 10-day moving average crossed below 50-day moving average on September 02, 2026
The 10-day moving average for MAZE crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MAZE as a result. In of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MAZE turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at .
MAZE moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MAZE broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MAZE entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in of 90 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.166) is normal, around the industry mean (20.583). MAZE's P/E Ratio (191.339) is considerably higher than the industry average of (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (443.835).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
